CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.

Authors You, B. et al.
Journal J Clin Oncol. 2022 Jul 22;JCO2200430. doi: 10.1200/JCO.22.00430. Online ahead of print. Lien

815MO The impact of chemosensitivity assessed by modeled CA-125 KELIM™ on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients.

Authors You, B. et al.
Journal Annals of Oncology, Volume 31, S616 Lien

847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM™, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands.

Authors Van Wagensveld, L. et al.
Journal Annals of Oncology, Volume 31, S633 Lien

751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM™ in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group.

Authors Corbaux, P. et al.
Journal Annals of Oncology, Volume 32, S744 Lien

The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.

Authors You, B et al.
Journal Cancer Treatment Reviews, Volume 100, 102294 Lien

Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM™-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.

Authors You, B et al.
Journal Journal of Clinical Oncology 39(15_suppl): 5530-5530 Lien

CA-125 ELIMination rate constant K (KELIM™) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.

Authors You, B et al.
Journal Clin Cancer Res. 2020 Mar 24. pii: clincanres.0054.2020 Lien

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Authors Colomban, Tod, Leary, Ray-Coquard, Lortholary, Hardy-Bessard, Pfisterer, Du Bois, Kurzeder, Burges, Péron, Freyer, You B
Journal Clin Cancer Res. 2019 Sep 1 Lien

The predictive value of the CA-125 modeled kinetic parameter KELIM™ is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials).

Authors B.M. You O. Colomban M. Tod I.L. Ray-Coquard A. Lortholary A.C. Hardy-Bessard A. Du Bois J. Huober W. Meier C. Kurzeder
Journal Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 857PD Lien

Two prognostic populations of ovarian cancer patients defined by CA-125 modeled kinetic parameter KELIM™ (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/ MRC CTU/GCIG trials).

Authors Benoit You, Olivier Colomban, Gilles Freyer, Alexandra Leary, Isabelle Laure Ray-Coquard, Alain Lortholary, Anne Claire Hardy Bessard, Jacobus Pfisterer, Andreas Du Bois, Christian Kurzeder, Alexander Burges, and Michel Tod
Journal Journal of Clinical Oncology 2017 35:15_suppl, 5554-5554

Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.

Authors You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ.
Journal Br J Cancer. 2013 May 14;108(9):1810-6. PubMed PMID: 23591194

Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.

Authors You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F.
Journal Ann Oncol. 2010 Aug;21(8):1643-50. PubMed PMID: 20154304

Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.

Authors You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P.
Journal Prostate. 2009 Sep 1;69(12):1325-33. PubMed PMID: 19475643

A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

Authors You B, Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O
Journal Annals of Oncology 25: 41–56, 2014 PubMed PMID: 24356619